Statistical analysis of PML incidences of natalizumab-treated patients from 2009 to 2016: outcomes after introduction of the Stratify JCVA® DxSelect™ antibody assay

被引:17
作者
Campagnolo, Denise [1 ]
Dong, Qunming [1 ]
Lee, Lily [1 ]
Ho, Pei-Ran [1 ]
Amarante, Diogo [1 ]
Koendgen, Harold [1 ]
机构
[1] Biogen, 14 Cambridge Ctr, Cambridge, MA 02142 USA
关键词
Progressive Multifocal Leukoencephalopathy; Natalizumab; Progressive Multifocal Leukoencephalopathy; Antibody Assay; John Cunningham Virus;
D O I
10.1007/s13365-016-0482-z
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
引用
收藏
页码:880 / 881
页数:2
相关论文
共 4 条
[1]  
[Anonymous], 2016, TYS NAT
[2]  
Plavina T, 2013, 27 ANN M CONS MULT S
[3]   Anti-JC Virus Antibody Levels in Serum or Plasma Further Define Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy [J].
Plavina, Tatiana ;
Subramanyam, Meena ;
Bloomgren, Gary ;
Richman, Sandra ;
Pace, Amy ;
Lee, Sophia ;
Schlain, Brian ;
Campagnolo, Denise ;
Belachew, Shibeshih ;
Ticho, Barry .
ANNALS OF NEUROLOGY, 2014, 76 (06) :802-812
[4]  
Werner M. H., 2016, J NEUROVIROL